# BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES

> **NCT03658135** · PHASE1 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 22 (actual)

## Conditions studied

- Primary Tauopathies
- Corticobasal Degeneration Syndrome
- Frontotemporal Lobar Degeneration With Tau Inclusions
- MAPT Mutation Carriers, Symptomatic
- Traumatic Encephalopathy Syndrome
- Nonfluent Aphasia, Progressive

## Interventions

- **DRUG:** BIIB092
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03658135
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-12
- **Primary completion:** 2019-12-13
- **Final completion:** 2019-12-13
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** BIIB092 program discontinued
- **Last updated:** 2019-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03658135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03658135, "BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03658135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*